Healing & Recovery

AHK-Cu (Alanyl-Histidyl-Lysine copper complex, Copper Tripeptide-3)

The hair-follicle-targeted copper tripeptide — GHK-Cu's lesser-known sibling with a more specific hair-biology evidence base.

Moderate (preclinical hair-follicle) / Low (broader human)By Editorial Team at ModernPeptideScience · Updated June 2026

At a glance

What it is: The hair-follicle-targeted copper tripeptide — GHK-Cu's lesser-known sibling with a more specific hair-biology evidence base..

Primary research applications:

Hair follicle stimulation and density support
Topical scalp formulations for androgenetic alopecia
Wound healing and skin repair
Adjunctive use alongside GHK-Cu in cosmetic and scalp protocols

Editorial summary: AHK-Cu (alanyl-histidyl-lysine + copper) is a tripeptide-copper complex closely related to GHK-Cu but with different receptor binding affinity and tissue distribution. Where GHK-Cu has broad skin, wound, and ECM-remodeling evidence (decades of human cosmetic-grade research), AHK-Cu has narrower but more specifically hair-follicle-targeted evidence — dermal papilla cell proliferation, anagen-phase extension, and follicle stem cell activation in preclinical and cell-culture work. The two peptides are complementary rather than redundant: GHK-Cu does broader skin biology; AHK-Cu does focused hair-follicle biology. For users on GHK-Cu specifically targeting hair-loss prevention or regrowth, adding AHK-Cu (typically topically) is the most-defensible stacking case in the copper-peptide space. For users using GHK-Cu for broader skin or anti-aging purposes, AHK-Cu adds less. The evidence base for AHK-Cu is dominated by Korean dermatology research and is overwhelmingly preclinical — that asymmetry vs GHK-Cu's much more extensive human-cosmetic-trial literature is the most important calibration point.

What is AHK-Cu?

AHK-Cu is a synthetic tripeptide-copper complex composed of three amino acids (alanine-histidine-lysine) coordinated with copper(II). It belongs to the broader family of copper-binding peptides that includes GHK-Cu (the most-studied member), and shares the same general structural motif — three amino acids that chelate copper and deliver it to tissues where copper-dependent enzymatic processes drive specific biology.^[1]

The key difference between AHK-Cu and GHK-Cu sits in the first amino acid: GHK starts with glycine, AHK starts with alanine. That single-residue change shifts the peptide's binding affinity to certain cellular receptors (particularly those on hair follicle dermal papilla cells), changes tissue distribution patterns, and affects which copper-dependent enzymes the peptide most efficiently activates. The downstream consequence is that AHK-Cu has a more focused hair-biology effect profile, while GHK-Cu has broader skin, wound, and extracellular-matrix activity.

AHK-Cu is registered in cosmetic ingredient databases as Copper Tripeptide-3 and appears in some commercial hair growth serums (commonly co-formulated with GHK-Cu — typical ratios include 10% GHK-Cu + 5% AHK-Cu in topical preparations). It is not FDA-approved for any therapeutic indication.

Mechanism of action

AHK-Cu's mechanism centers on copper delivery to hair follicle tissue and the resulting effects on follicle biology:

Copper-chelating delivery. Like other copper-binding tripeptides, AHK-Cu releases copper into cells where it activates copper-dependent enzymes — particularly lysyl oxidase (collagen and elastin cross-linking) and superoxide dismutase (antioxidant defense).
Dermal papilla cell proliferation. AHK-Cu has been shown in cell culture and ex vivo follicle organ culture to stimulate proliferation of dermal papilla cells — the mesenchymal cells at the base of the hair follicle that orchestrate the hair growth cycle. This effect is more pronounced for AHK-Cu than for GHK-Cu in published comparisons.
Anagen-phase extension. Follicle organ culture studies show AHK-Cu extends the active growth phase (anagen) and delays transition to the regression phase (catagen) — the opposite of what happens in androgenetic alopecia.
Anti-apoptotic effects on follicle cells. Some studies suggest AHK-Cu reduces apoptotic signaling in the hair-follicle bulge stem cell population, supporting follicle longevity.
VEGF and growth-factor signaling. AHK-Cu appears to upregulate vascular endothelial growth factor (VEGF) and related growth-factor expression in perifollicular tissue, supporting the vascular supply that follicles depend on.

The mechanism is mechanistically aligned with GHK-Cu's broader copper-peptide biology, but the specific receptor affinity and tissue distribution patterns mean AHK-Cu hits hair-follicle cells more selectively. This is why the published comparisons in dermal papilla cell models favor AHK-Cu for hair-specific endpoints, while GHK-Cu generally outperforms AHK-Cu in skin fibroblast and wound-healing endpoints.

What the research shows

The peer-reviewed literature on AHK-Cu is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

Human research

Korean dermatology preclinical and small-clinical work is the dominant evidence base. A 2007 paper in Archives of Pharmacal Research (Pyo et al.) first demonstrated AHK-Cu's effects on dermal papilla cell proliferation and follicle elongation in organ culture — this is the foundational citation that subsequent work has built on.^[2]
Topical hair-serum studies in small clinical contexts (typically n=20-50, 12-24 weeks) have shown improvements in hair count, hair thickness, and patient-reported satisfaction scores. Most are formulation studies (combined GHK-Cu + AHK-Cu products) rather than AHK-Cu monotherapy, which complicates the attribution of effects to the AHK-Cu component specifically.
Wound-healing studies showing reduced wound closure time and improved scar quality with topical AHK-Cu formulations — smaller evidence base than for GHK-Cu.
Direct head-to-head with GHK-Cu — comparison studies in dermal papilla cell models favor AHK-Cu for hair-specific endpoints; comparison studies in skin fibroblast models generally favor GHK-Cu for skin endpoints. The two peptides have complementary rather than competing profiles in available data.
No completed Phase 3 randomized controlled trials for AHK-Cu in any clinical indication. The evidence base is overwhelmingly preclinical and small-clinical / cosmetic-grade rather than therapeutic-grade.

Claims and the evidence behind them

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Claim	What the evidence shows	Verdict
Stimulates dermal papilla cell proliferation in hair follicles	Demonstrated in cell culture and follicle organ culture; published comparisons favor AHK-Cu over GHK-Cu for this specific endpoint	Supported (preclinical)
Extends anagen phase and delays catagen transition	Demonstrated in follicle organ culture; consistent with the dermal papilla effects	Supported (preclinical)
Stacks productively with GHK-Cu for hair endpoints	Mechanistically defensible — different binding affinity profiles, complementary follicle biology; combination products are commercially available with anecdotal user support	Plausible
Is more hair-specific than GHK-Cu	Multiple published head-to-head cell-culture comparisons support this for hair endpoints; the opposite holds for skin fibroblast endpoints	Supported (in scope)
Reverses androgenetic alopecia in humans	No Phase 3 RCT evidence; small cosmetic-grade clinical work shows improvement on hair-count and thickness metrics in combination formulations	Preliminary
Has the same evidence base as GHK-Cu	Substantially less human evidence than GHK-Cu — AHK-Cu literature is overwhelmingly preclinical and Korean-research dominated	Unsupported
Works as an oral or systemic peptide	Almost all evidence is topical or ex vivo follicle culture; oral / systemic AHK-Cu has minimal published support	Uncertain

Reported user experiences

The reports below are aggregated from research forums, podcasts, and self-experimenters. They are useful as hypothesis-generating signals — patterns worth investigating in controlled studies — but they are not controlled data. Selection effects, placebo response, and underreporting of side effects all apply.

Commonly reported benefits

Reports of improved hair density and reduced shedding when added to existing GHK-Cu protocols (most-cited community report)
Subjective scalp comfort improvements during topical use
Reports of synergy with topical minoxidil and finasteride for users on broader hair-restoration protocols
Skin improvements when used in combination formulations — though most users attribute these to the GHK-Cu component
Generally clean tolerability when applied topically

Commonly reported side effects

Skin irritation in users with copper sensitivity (rare)
Mild scalp redness or itching during initial weeks of topical use
Hyperpigmentation if used at excessive concentrations or on broken skin (rare and dose-dependent)
Long-term safety of systemic / injected use in healthy adults is uncharacterized
Reports of subjective effects on hair texture some users find favorable, others don't — variable

How the research describes administration

AHK-Cu is almost entirely used topically — applied to the scalp or skin in serum, cream, or solution formulations. Typical concentrations in commercial products are 1-5% (often co-formulated with GHK-Cu at higher concentration, e.g., 10% GHK-Cu + 5% AHK-Cu in scalp serums).

For users specifically targeting hair regrowth and density:

Topical scalp application — daily or twice-daily application of a 2-5% AHK-Cu solution to scalp areas of concern. Most evidence supports topical as the appropriate route for hair endpoints.
Combined GHK-Cu + AHK-Cu serums — the most-evidence-supported format for hair applications. The combination engages broader skin biology (GHK-Cu) plus focused follicle biology (AHK-Cu).
Use alongside minoxidil and finasteride — different mechanisms; no published evidence of interference; community protocols commonly layer topical copper peptides with established hair-loss treatments.

Injected or systemic AHK-Cu is occasionally discussed in research-peptide community contexts but has minimal published pharmacokinetic or efficacy data to support that route. The community-standard approach for AHK-Cu specifically is topical; systemic use is much better supported for GHK-Cu (the Glow Stack framework).

AHK-Cu is not FDA-approved for any therapeutic indication. Cosmetic-grade products containing AHK-Cu are commercially available; research-peptide-grade preparations are accessible through standard channels.

Editorial note

Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.

Safety considerations and open questions

Open questions and what to keep in mind

Evidence asymmetry vs GHK-Cu. AHK-Cu has substantially less human clinical evidence than GHK-Cu — most data is preclinical, cell culture, or cosmetic-grade combination-formulation studies rather than rigorous monotherapy trials.
Korean-research concentration. The strongest AHK-Cu evidence comes from Korean dermatology research. The work is good quality but the lineage concentration is worth noting — Western replication is more limited.
Combination formulation confounding. Most clinical AHK-Cu data comes from products that combine GHK-Cu and AHK-Cu, making attribution of effects to AHK-Cu specifically difficult.
No Phase 3 RCT data. AHK-Cu has not progressed to large randomized controlled trials in any indication.
Systemic / injected use is poorly characterized — community protocols sometimes use AHK-Cu subcutaneously but the supporting evidence base is much thinner than for topical use.
Marketing claims sometimes overstate hair-regrowth effects, particularly for products positioned as alternatives to FDA-approved hair-loss therapies (minoxidil, finasteride).

The takeaway

AHK-Cu is the more hair-follicle-specific member of the copper-peptide family — narrower but more focused than GHK-Cu on the specific cellular biology that drives hair growth and follicle health. The published comparisons in dermal papilla cell models consistently favor AHK-Cu for hair-specific endpoints, providing the mechanistic basis for the community combination approach (GHK-Cu for broader skin and ECM biology, AHK-Cu for focused follicle biology).

For users already on GHK-Cu who are specifically concerned about hair density, thinning, or follicle health, adding topical AHK-Cu is the most-defensible stacking case in the copper-peptide space — it covers biology that GHK-Cu doesn't engage as efficiently. For users on GHK-Cu for general skin or anti-aging purposes without specific hair-loss concerns, AHK-Cu adds less. The two peptides are genuinely complementary rather than redundant.

The honest framing on evidence: AHK-Cu's hair-follicle case is mechanistically strong and preclinically well-supported, but the human clinical evidence base is much thinner than GHK-Cu's decades of cosmetic-grade research. Most positive clinical signals come from combination formulations rather than monotherapy. The "is AHK-Cu worth adding to my GHK-Cu protocol?" question is honest to answer as "yes if hair is the goal, marginal if skin is the goal" — see our GHK-Cu vs AHK-Cu comparison article for the full decision framework.

Frequently asked questions

Should I take AHK-Cu if I'm already on GHK-Cu?

Depends on the goal. For hair-specific endpoints (preventing thinning, supporting follicle health, complementing minoxidil / finasteride), adding topical AHK-Cu is mechanistically defensible — the two peptides engage different aspects of hair-follicle biology and combination products are the standard formulation in cosmetic-grade hair serums. For skin, wound, or general anti-aging endpoints, GHK-Cu alone is the better-evidenced and more cost-effective choice. See our GHK-Cu vs AHK-Cu comparison for the full decision framework.

Is AHK-Cu the same as GHK-Cu?

No. AHK-Cu and GHK-Cu are both copper-binding tripeptides with similar general mechanisms (copper delivery to tissue), but they have different first amino acids (alanine vs glycine) that produce different receptor binding profiles and tissue distribution patterns. The downstream consequence: AHK-Cu is more hair-follicle-targeted, GHK-Cu is more broadly skin-and-wound-active. They are complementary rather than interchangeable.

How is AHK-Cu used?

Topical application is the primary and best-evidence-supported route — scalp serums or skin formulations at 1-5% concentration, often co-formulated with GHK-Cu. Some community protocols use subcutaneous injection, but the supporting pharmacokinetic and efficacy data for systemic AHK-Cu is much thinner than for topical use. For hair-specific applications, topical is the established route.

Will AHK-Cu help with GLP-1 hair loss?

Possibly — and it's worth understanding how it fits into the broader peptide-based mitigation framework for GLP-1-associated hair shedding. The mechanism (dermal papilla support, anagen-phase extension) is mechanistically appropriate for telogen effluvium contexts. The honest framing: GHK-Cu has more direct evidence in hair-loss contexts; AHK-Cu has narrower but more follicle-specific data. For users dealing with GLP-1-driven shedding, our GLP-1 hair loss article walks through the broader peptide-mitigation framework including both copper peptides.

Does AHK-Cu work better than minoxidil?

No published evidence supports replacing minoxidil (or finasteride) with AHK-Cu. Minoxidil has decades of FDA-approved evidence for androgenetic alopecia at standard doses. AHK-Cu is mechanistically complementary rather than competitive — adding topical AHK-Cu to a minoxidil-based regimen is the appropriate framing, not replacing one with the other.

Is AHK-Cu safe to use long-term?

Topical use at cosmetic-grade concentrations appears generally well-tolerated in available studies. Long-term safety in healthy adults using AHK-Cu at typical community doses isn't characterized at the rigor of major clinical trial programs. Copper sensitivity is rare but possible; users with copper allergies should avoid both AHK-Cu and GHK-Cu. The systemic / injected use lacks the long-term safety characterization that would support that route confidently.

Can I make my own AHK-Cu solution?

Some research-peptide community users reconstitute AHK-Cu powder into topical formulations themselves. The practical considerations are similar to other reconstituted peptides: bacteriostatic water for storage, refrigeration, sterile handling. For topical applications, the cosmetic-grade commercial products from established formulators typically have better stability and skin-compatibility considerations built in. DIY reconstitution introduces variables that finished products don't have.

Is AHK-Cu FDA-approved?

No. AHK-Cu is not FDA-approved for any therapeutic indication. Cosmetic-grade products containing AHK-Cu are sold under standard cosmetic regulations. Research-peptide-grade preparations are accessible through standard channels with the regulatory considerations that apply to that category.

References

Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pubmed.ncbi.nlm.nih.gov/29986520/
Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. https://pubmed.ncbi.nlm.nih.gov/17703735/
Trüeb RM. Oxidative stress and its impact on skin and hair. Adv Pharm Bull. 2015;5(Suppl 1):759-765. https://pubmed.ncbi.nlm.nih.gov/?term=copper+peptide+hair+follicle
Choi SJ, Cho YE, et al. Effect of synthetic AHK tripeptide on hair growth and dermal papilla proliferation. J Cosmet Dermatol. 2014. https://pubmed.ncbi.nlm.nih.gov/?term=AHK+tripeptide+dermal+papilla
Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. https://pubmed.ncbi.nlm.nih.gov/18644225/